Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + lenalidomide + dexamethasone induction and extended consolidation with lenalidomide maintenance in newly diagnosed multiple myeloma
2014-003467-37Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Stringent complete response rate. Started Jun 2015; status: completed.
02
Drugs
ixazomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-003467-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003467-37.